This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jeevanandam, V. Articles by Kantrowitz, A. Search for Related Content PubMed PubMed Citation Articles by Jeevanandam, V. Articles by Kantrowitz, A. Related Collections Congestive CV surgery: transplantation, ventricular assistance, cardiomyopathy Chronic ischemic heart disease

(Circulation. 2002;106:I-183.)
© 2002 American Heart Association, Inc.

Thoracic Transplantation and Mechanical Support for Congestive Heart Failure

Circulatory Assistance With a Permanent Implantable IABP: Initial Human Experience

Valluvan Jeevanandam, MD; David Jayakar, MD; Allen S. Anderson, MD; Suzanne Martin, ACNP; William Piccione, Jr, MD; A.L. Heroux, MD; J. Wynne, MD; Larry W. Stephenson, MD; Jack Hsu, MD; Paul S. Freed, MS; Adrian Kantrowitz, MD

From the University of Chicago, Chicago, Ill. (V.J., D.J., A.S.A., S.M., W.P., A.K.); Rush-Presbyterian, Chicago, Ill. (W.P., A.L.H.); Wayne State University, Detroit, Mich. (J.W., L.W.S.); and L.VAD Technology, Inc, Detroit, Mich. (J.H., P.S.F., A.K.).

Correspondence to Valluvan Jeevanandam, MD, University of Chicago, 5841 S. Maryland, M/C 5040, Chicago, IL 60637. E-mail jeevan{at}surgery.bsd.uchicago.edu

Abstract

Purpose The Kantrowitz CardioVAD^TM (KCV) is an electrically powered, pneumatically driven circulatory assist device which provides diastolic augmentation and systolic unloading to the failing heart. It consists of a 60cc-pumping chamber, a percutaneous access device (PAD), and an external controller. The pumping chamber, is surgically implanted in the descending thoracic aorta with the patient on cardiopulmonary bypass. Its physiologic function is analogous to that of the intra-aortic balloon pump (IABP).

Methods Between 1997 and 2000, 5 men (age 59 to 73) with end-stage cardiomyopathy refractory to maximal drug treatment and with documented hemodynamic improvement on an IABP were enrolled in a feasibility study.

Results Mean bypass time was 157 minute (range 120 to 196 minute); mean cross-clamp time was 101 minute (range 69 to 144). Patient 1 died intra-operatively. Compared with preoperative values, at 1 month, cardiac index increased (1.7 to 2.6 L/min/m²) and there were significant decreases in creatinine (2.6 to 1.5 mg/dL), pulmonary capillary wedge pressure (PCWP) (32 to 14 mm Hg), and right atrial pressure (RA) (19 to 9 mm Hg). NYHA class improved (IV to II). The mean increase in cardiac index with the KCV OFF to ON was 0.53 L/min/m² (36%). Two patients were discharged home. The device was used intermittently without thromboembolic complications. The only device related complications were attributed to PAD design and have been corrected.

Conclusion Our initial human trial demonstrates successful implantation of the KCV in end-stage patients, the ability of the device to be used intermittently without anticoagulation, and documents hemodynamic and functional improvement in the status of these patients.

Key Words: heart-assist device • heart failure • cardiomyopathy • inotropic agents